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ABSTRACT
Glioblastoma tumor initiating cells are believed to be the main drivers behind tumor 
recurrence, and therefore therapies that specifically manage this population are of great 
medical interest. In a previous work, we synthesized controlled release microspheres 
optimized for intracranial delivery of BMP7, and showed that these devices are able to 
stop the in vitro growth of a glioma cell line. Towards the translational development of 
this technology, we now explore these microspheres in further detail and characterize the 
mechanism of action and the in vivo therapeutic potential using tumor models relevant 
for the clinical setting: human primary glioblastoma cell lines. Our results show that 
BMP7 can stop the proliferation and block the self-renewal capacity of those primary 
cell lines that express the receptor BMPR1B. BMP7 was encapsulated in poly (lactic-co-
glycolic acid) microspheres in the form of a complex with heparin and Tetronic, and the 
formulation provided effective release for several weeks, a process controlled by carrier 
degradation. Data from xenografts confirmed reduced and delayed tumor formation 
for animals treated with BMP7-loaded microspheres. This effect was coincident with 
the activation of the canonical BMP signaling pathway. Importantly, tumors treated 
with BMP7-loaded microspheres also showed downregulation of several markers that 
may be related to a malignant stem cell-like phenotype: CD133+, Olig2, and GFAPδ. We 
also observed that tumors treated with BMP7-loaded microspheres showed enhanced 
expression of cell cycle inhibitors and reduced expression of the proliferation marker 
PCNA. In summary, BMP7-loaded controlled release microspheres are able to inhibit GBM 
growth and reduce malignancy markers. We envisage that this kind of selective therapy 
for tumor initiating cells could have a synergistic effect in combination with conventional 
cytoreductive therapy (chemo-, radiotherapy) or with immunotherapy.
INTRODUCTION
A glioblastoma (GBM) is a highly aggressive 
brain tumor characterized by its lack of response to 
conventional chemo-, radio-, and immunotherapies. 
Recent studies suggest that recurrence of GBM may be 
due to the therapeutic resistance of a subpopulation of 
undifferentiated GBM tumor-initiating cells  (GBM-
TICs). Consequently, it has been proposed that a potential 
treatment for GBM is to induce differentiation of 
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GBM-TICs to a more benign phenotype or to a cell type 
more amenable to standard therapies [1–3].
Bone morphogenetic proteins (BMPs) are among the 
most potent inducers of GBM-TIC differentiation. Indeed, 
BMPs have been considered non-cytotoxic therapeutic 
compounds that may be of use in preventing the growth and 
recurrence of GBM [4]. BMPs signal via specific serine/
threonine kinase receptors on the cell surface known as bone 
morphogenetic protein receptors (BMPRs). Both type-I and 
-II BMPRs are required for signal transduction. The type-I 
receptor BMPRIA preferentially binds ligands of the Dpp 
class, such as BMP2 and BMP4, whereas the type-I receptor 
BMPRIB binds ligands of the 60A class, such as BMP7. 
After ligand binding, the type-I/type-II receptor complex 
phosphorylates Smad1, 5 and 8 proteins that translocate 
to the nucleus to regulate target gene expression [5]. 
Previous studies have shown that treatment of GBM-TICs 
with BMP4 or BMP7 triggers Smad-mediated signaling, 
leading to the inhibition of cell proliferation, the induction 
of differentiation and a reduction of tumor formation in 
immunodeficient mice [4, 6, 7]. In a minority of GBMs 
displaying epigenetic silencing of the type I receptor 
BMPRIB, however, BMPs fail to induce differentiation 
but instead support the proliferation of GBM-TICs, thereby 
promoting tumorigenesis [8].
Despite this promising pharmacological profile, any 
attempt to use soluble BMPs as a GBM-TICs suppressor 
will face important shortcomings due to its fast in vivo 
erosion [9], and its incapacity to cross the blood-brain 
barrier [10]. To address this problem, we have recently 
reported the preparation of a microsphere formulation 
optimized for loading BMP7, and intended as an intracranial 
sustained release implant for managing GBM-TICs upon 
primary tumor resection [11]. These microspheres were 
able to release BMP7 for more than two months, and 
this released protein was able to stop the in vitro growth 
of a glioma cell line model. Although this cell line model 
(U87MG spheres) was interesting for screening purposes, 
however, the results were admittedly far from indicative of 
the therapeutic potential, and inadequate for analyzing the 
mechanism of action of the therapeutic device.
In this work, we provide further characterization of 
the structure and release mechanism of the microspheres, 
and we test the potential spectrum of applicability of our 
therapeutic device, its in vivo therapeutic potential, and 
mechanism of action. These activity/mechanistic studies 
were performed with primary GBM-TICs cultures from 
human glioblastoma, a clinically applicable model for 
addressing such questions.
RESULTS
BMP7 inhibits the sphere formation capacity of 
GBM-TICs expressing BMPR1B
Increasing evidence strongly supports a key role 
for BMP7 as a glioma growth inhibitor. In most tumors, 
treatment of GBM-TICs with BMP7 inhibits proliferation 
and promotes differentiation [4]; however, in a minority 
of GBMs, BMPs fail to induce differentiation of GBM-
TICs due to epigenetic silencing of BMPR1B [8]. In order 
to further define the effect of BMP7 on gliomagenesis, 
we tested 8 primary GBM-TIC cell lines (GBM1–8) 
established in our laboratory from surgically resected 
human specimens of adult GBM patients. GBM1–8 
primary cell lines grow in suspension as non-adherent 
spheres and proliferate in serum-free media supplemented 
with EGF and bFGF (Figure 1A).
Since previous studies using GBM-TICs have 
shown tumor-to-tumor variation in the expression of BMP 
receptors, we first determined the mRNA levels of BMP7, 
BMPR1A, BMPR1B and BMPR2 genes by real-time qRT-
PCR in our primary cell lines. We found that BMPR2 
and BMPR1A were expressed in all the GBM-TICs, 
albeit at different levels. BMP7 itself was expressed in 
all but one sample (GBM7), whereas BMPR1B was only 
significantly expressed in three cultures: GBM4, GBM6 
and GBM8 (Figure 1B). Consistently, only GBM6 and 
GBM8 (GBM4 could not be tested) were able to respond 
to BMP7 by diminishing their clonogenic capacity in a 
sphere formation assay (Figure 1C). The most sensitive 
cell line, GBM8, expressed the highest levels of the BMP 
receptor genes and was selected to pursue our study.
BMP7 reduces GBM-TIC proliferation, 
clonogenicity and self-renewal capacity
As a consequence of having functional receptors, 
BMP7 induced canonical BMP signaling in GBM8, as 
evidenced by both their translocation to the nucleus 
(Figure 2A) and their transient phosphorylation of the 
Smad1, 5, 8 effectors at 6 h (Figure 2B). The presence 
of BMP7 severely impaired long-term expansion of 
GBM8 sphere cultures, as we saw from the sphere 
cultures expanded in vitro for three cell passages (21 
days, Figure 2C).
We then performed a sphere formation assay 
on GBM8 cells seeded at low density in the presence 
of increasing doses of BMP7 (Figure 2D). We found 
a decrease in the number of BMP7 treated spheres 
compared to the control group (Figure 2E). The size of 
the spheres derived was also decreased (Figure 2F). This 
in vitro phenotype reflects the inhibited proliferative 
activity of the GBM-TICs in the presence of 50 ng/mL 
and 100 ng/mL of BMP7. To determine whether BMP7 
regulates GBM-TIC self-renewal, spheres that had been 
grown in BMP7 were dissociated and plated in the 
presence of mitogens but without the BMP ligand (Figure 
2G). As a control, the same experiment was performed 
with cells not pretreated with BMP7. As shown in Figure 
2H and 2I, the number of spheres that were able to grow 
in BMP7 pretreated cultures was significantly lower, 
indicating that cells had been switched to a phenotype 
with decreased self-renewal capacity.
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Figure 1: BMP7 decreases sphere formation in primary GBM-TIC cultures expressing BMPR1B. (A) Representative 
phase-contrast images of the different GBM-TIC cultures used in the study. Scale bar: 100 μm. (B) BMPR1A, BMPR1B, BMPR2 and BMP7 
relative mRNA expression levels of the cultures. GAPDH was used as the RT-qPCR housekeeping gene. (C) Quantification of the GBM-
TIC culture capacity to form spheres in the presence/absence of 50 ng/mL of BMP7. Cells were seeded at low density in 96-well plates and 
spheres were counted after 7 days. ***p < 0.001.
Oncotarget10953www.impactjournals.com/oncotarget
Figure 2: BMP7 decreases cell growth, sphere formation and self-renewal and it exerts its action via canonical signaling.  
(A) Immunocytochemistry analysis of p-Smad1, 5, 8 location (red) after 6 h treatment of the culture with 50ng/mL of BMP7. DAPI stain is 
shown in blue. (B) Western blot analysis of p-Smad1, 5, 8 and total Smad1, 5, 8 after addition of 50ng/mL of BMP7 to the GMB culture. 
β-actin expression was used as the loading control. (C) Long-term growth curve of GBM8-TIC culture expanded in vitro over 3 weeks (n = 3). 
(D–F) Sphere formation assay. (D) Diagram representing the strategy used to assess the effect of BMP7 on the sphere formation capacity of 
the GBM culture in the absence or in the presence of two different BMP7 concentrations (n = 3) (E) Quantification of the number of spheres. 
(F) Percentage of small, medium and large spheres that appear in each condition. (G–H) Self-renewal assay. Quantification of the GBM-
TIC capacity to form secondary spheres after BMP7 removal. (G) Schematic representation of the assay timeline. (H) Number of secondary 
spheres. (I) Representative image of a sphere formation assay. ***p < 0.001. Scale bar in A: 25 μm. Scale bar in I: 100 μm.
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Microspheres with BMP7 prepared using a 
nanocomplex encapsulation method
Previous studies have shown that BMP7 can 
be incorporated into poly(lactic-co-glycolic) (PLGA) 
microspheres in the form of a heparin-Tetronic complex, a 
method named nanocomplex encapsulation. This method 
results in high protein encapsulation and controlled 
release properties for several weeks [11]. We selected this 
formulation for the in vivo experiments (Section 3.4), and 
we characterized the microsphere system in further detail.
Microspheres loaded with BMP7 presented a 
spherical morphology, regular surface, and absence 
of matrix pores (Figure 3A, 3B). Incubation of the 
microspheres under hydrolytic conditions resulted in 
particle breakup, and disclosed a frequently hollow inner 
structure (Figure 3C, 3D). Particle size followed a normal 
distribution (r2=0.987), with an average of 81 ± 24 μm 
(Figure 3E). Microsphere yield was 93.5 ± 5.1%. FTIR 
analysis of the microspheres showed a spectrum consistent 
with a mixed PLGA/Tetronic composition. A redshift of 
the hydroxide band, between 3455 cm−1 (PLGA), 3509 
cm−1 (Tetronic) and 3397 cm−1 (microspheres) suggested 
a non-covalent interaction between these two materials 
(results not shown).
We then characterized microsphere erosion under 
release conditions (PBS 1% BSA, 37°C) to understand its 
role in BMP7 release. SEM images showed microsphere 
erosion over a period of 4 weeks. At the starting point 
the microspheres were characterized by a regular and flat 
surface (Figure 4A). At one week, signs of pore formation 
were evident on the particle surface (Figure 4B). By 
two weeks, particle breakup was observed, revealing a 
porous inner structure (Figure 4C), and frequently hollow 
inner structures (Figure 3C, 3D). By four weeks, particle 
structure had often collapsed completely (Figure 4D). The 
microspheres released BMP7 at all the time points studied 
by SEM (Figure 4E), confirming more than 4 weeks of 
sustained protein release.
BMP7-loaded microspheres act as a glioma 
tumor suppressor in vivo
In order to test the effect of BMP7 on tumor growth, 
1.5 × 106 cells mixed with microspheres (blank, 0.01% 
BMP7, and 0.05% BMP7 loading) were subcutaneously 
transplanted into nude mice flanks. The tumor sizes were 
measured from the moment they were detectable in order 
to calculate their growth curves. While control tumors 
and 0.01% BMP7 microsphere treated tumors were 
of similar size, the 0.05% BMP7 microsphere treated 
tumors presented a reduced volume upon extraction at the 
endpoint of the experiment (Figure 5A and 5B), and an 
impaired growth rate (Figure 5C).
To further confirm the effect of BMP7 on tumor 
cells in vivo, the downstream signaling activation of 
Smad1, 5, 8 was analyzed by western blot using a specific 
antibody against the phosphorylated protein. Tumors 
implanted with 0.05% BMP7 microspheres showed higher 
activation of the canonical BMP route (Figure 6A and 6B). 
We also explored whether BMP7 signaling in tumors lead 
to the differentiation of tumor initiating cells, as suggested 
by other authors. We did not find specific differentiation 
genes upregulated at the mRNA level (GFAPα or Tubb3, 
data not shown), but we confirmed a downregulation of 
stem cell markers such as SOX2, CD133, NESTIN, OLIG2 
and GFAPδ. Consistently, we observed overexpression of 
the cell cycle negative regulators CDKN1A and CDKN2A, 
and downregulation of the proliferation cell marker PCNA 
(Figure 6C).
Figure 3: Microsphere morphology and structure. Scanning electron microscopy images of microsphere populations 
(A, C), and individual microspheres (B, D). Images of microspheres after preparation (A, B), and after partial matrix hydrolysis in 
PBS at 37°C (C, D). Graph (E) is an accumulated frequency plot of the microsphere particle size distribution.
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We then analyzed the histology of the tumors by 
staining tumor tissue sections with hematoxilin-eosin 
(Figure 7A). Although the size of the tumors was smaller 
in the BMP7 treated mice, we found no difference at 
the cellular level. All the tumors had the same rate of 
cellularity, glial differentiation, and vascular proliferation, 
and moreover, they all formed pseudopallisade necrosis 
(Figure 7B). When we quantified the number of mitosis and 
apoptosis per 40x field, the differences between control and 
treated tumors were not statistically significant (Figure 7C).
DISCUSSION
Despite recent progress in diagnostic and 
therapeutic strategies, GBM remains one of the most 
lethal human tumors due to inevitable recurrence [14, 15]. 
One of the obstacles to developing effective therapies for 
GBM patients arises from the diversity of glioblastoma 
cell populations. Cellular heterogeneity mainly results 
from the stepwise accumulation of genetic alterations, 
and from the existence of a hierarchical tumor cell 
Figure 4: Microsphere morphology and structure during degradation in PBS (pH 7.4) BSA 1% (w/v) at 37°C. Images 
taken at the starting point of the experiment (A), after 1 week (B), 2 weeks (C) and 4 weeks (D). (E) BMP7 concentration released at these 
time points (distributive data) was measured by ELISA.
Figure 5: BMP7 released from the particles decreased the xenograft growth of GBM cells in the athymic nude 
mice. Microspheres (MPs) were loaded with heparin (Blank), 0.01% (w/w) BMP7 or 0.05% (w/w) BMP7. The sample value (n) for 
each group was Blank n = 4, 0.01% BMP7 n = 6 and 0.05% BMP7 n = 6. (A) Representative picture of the tumors on the last day of the 
experiment. Not all the mice were alive at the end of the experiment for the picture. (B) Graph represents the tumor volume measured every 
4–5 days. (C) Final tumor volume measurements. *p < 0.05.
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Figure 6: BMP signaling and gene expression analysis of the GBM xenografts. (A) Western blot analysis of p-Smad1, 5, 8 
and total Smad1, 5, 8 in the tumors at the end of the experiment. β-actin was used as the loading control. (B) Western blot quantification, 
the amount of p-Smad1, 5, 8 is shown relative to the amount of total-Smad1, 5, 8. n = 3 independent tumors. (C) CD133, SOX2, OLIG2, 
GFAPδ, NESTIN, and CDKN1A, CDKN2A and PCNA relative mRNA expression levels of the tumor tissue. GAPDH was used as the 
RTqPCR housekeeping gene. n = 3 independent tumors. *p < 0.05, **p < 0.01.
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Figure 7: Histologic analysis of the GBM xenograft tumors treated with or without BMP7. (A) Representative 
hematoxylin and eosin (H&E) images of paraffin-embedded tumor tissue sections. 5X, 10X and 40X images are shown. (B) Estimation 
of the amount of cellularity, proliferation, pseudopallisade necrosis, glial differentiation, vascular proliferation and multinucleated giant 
cells. (C) Quantification of mitosis: number of mitosis figures per 40X field (average ±SEM of 10 fields). Quantification of apoptosis: 
number of apoptosis figures per 40X field (average ±SEM of 10 fields).
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organization that includes stem-like cells (the tumor-
initiating cells, TICs), precursors and differentiated cells 
[16]. Among the diverse GBM cell types, TICs are likely 
responsible for rapid tumor relapse given that they are 
radiation and chemotherapy resistant. Consequently, it 
has been widely suggested that forcing differentiation 
of stem-like GBM-TICs could be beneficial in stopping 
tumor growth or making the tumor more sensitive to 
standard therapies [1, 2, 8, 17].
The developmental pathways implicated in stem 
cell differentiation can be exploited in order to induce 
differentiation of GBM-TICs. Among these pathways, 
BMPs have a large therapeutic potential given that they 
have been previously linked to tumor suppression in glial 
tumors. It has been reported that: (1) BMP ligands are 
differentially expressed in tumor versus healthy tissue 
with a neat clinical relevance [18, 19]; (2) activation 
of the BMP pathway reduces glioma cell proliferation 
in vitro and in vivo and induces differentiation of the 
GBM-TICs [4, 7, 20–22] and (3) BMPs render GBM-
TICs more susceptible to conventional therapy [23, 24] 
(for a review see [25]).
In the low cell density in vitro assays, our data clearly 
shows that canonical signaling downstream of BMP7 
decreases GBM-TIC self-renewal and proliferation, which 
is in accordance with previous studies [6, 7, 21]. We also 
show that the expression of BMPR1B is essential for the 
responsiveness of the cells. A recent report [9] showed that 
20% of GBM tumors have CpG methylation in the BMPR1B 
promoter, which results in its epigenetic silencing. In primary 
human GBM-TICs without BMPR1B expression, BMP 
treatment increased proliferation while forced expression 
of BMPR1B restored the normal differentiation capacity 
of the TICs. In our study, only 2 out of 8 primary GBM-
TICs cultures (25%) responded to BMP7 treatment, and 
those were the ones with a high expression of BMPR1B 
receptor. Contrary to Lee et al. [9], we did not observe 
over-proliferation in response to BMP7 in those GBM-TIC 
cultures with no detectable levels of BMPR1B expression. 
This difference might be related to the different morphogen 
investigated in this study and our own (BMP4 vs. BMP7), 
and their transduced signal upon BMPR1A binding.
Despite the interesting pharmacological action 
of BMP7, its medical use in GBM is practically limited 
by an unfavorable biopharmaceutical profile. We 
have recently reported the design of a microsphere 
formulation for the intracranial delivery of BMP7 with 
suitable encapsulation and controlled release properties 
[11]. We argued that the delivery characteristics of 
these microspheres resulted from the encapsulation of 
BMP7 integrated in nanocomplexes with heparin and a 
polyethylenoxyde derivative. Growth factor release as a 
complex with heparin help to stabilize these proteins for 
prolonged action [26], while polyoxyethylene derivatives 
can protect proteins during encapsulation in hydrophobic 
matrices [27]. With this technology, the interaction 
between an anionic heparin/BMP7 complex and a cationic 
polyethylenoxyde derivative (Tetronic) is further enforced 
by ionic bonding.
Microscopy analysis showed that the microspheres 
prepared by the nanocomplex encapsulation method are 
spherical, regular and many present a hollow interior. 
Spectroscopic analysis confirmed interaction between 
the biodegradable PLGA matrix and Tetronic; this good 
interpolymer compatibility can be related to the efficient 
encapsulation of the BMP7/heparin/Tetronic complex in 
the PLGA matrix. Microsphere matrix degraded in vitro 
at 37°C over a period of > 4 weeks, a process triggering 
BMP7 release [28]. We have previously showed how 
BMP7 released from the microspheres can stop cell 
growth in spheres from the U87MG glioma cell line [11], 
an interesting cell model for screening purposes, but 
limited for predicting the system’s therapeutic potential, 
and for analyzing the cellular events behind the observed 
tumor suppressive effects [29]. We addressed these 
questions here by interrogating a more advance tumor 
model of primary GBM-TICs cell lines established in our 
laboratory from surgically resected human specimens of 
adult GBM patients. The effect of BMP7 was tested not 
only in vitro but also in vivo.
We tested the effect of BMP7 in vivo by concomitant 
subcutaneous transplantation of GBM-TICs and BMP7-
loaded microspheres into nude mice. This setup is a 
clinically relevant model for addressing the therapeutic 
potential of BMP7 since GBM-TIC primary cell lines 
are able to generate tumors that very closely resemble 
the original patient’s GBM except for the invasive 
properties (Zahonero and Sánchez, unpublished). We 
found a net reduction in tumor growth in vivo when cells 
were exposed to the microspheres releasing BMP7. Only 
microspheres with 0.05% w/w of BMP7 presented a 
statistically significant reduced volume during the whole 
experiment and at the endpoint, indicating that low BMP7 
doses are not sufficient to counteract tumor growth. 
Although we began to measure the tumor sizes when the 
tumors from all the conditions were detectable, we have to 
point out that 0.05% BMP7 tumors arose later in time than 
0.01% BMP7 and control tumors. The lag time between 
the subcutaneous transplantation and the appearance of a 
detectable tumor mass was 40 days for control and 0.01% 
BMP7 tumors, while 0.05% BMP7 tumors were visible 
approximately 10 days later. Animals were sacrificed at 
day 63 after tumor injection. Taking into account that the 
microsphere preparation efficiently releases BMP7 in vitro 
for 40–60 days (Figure 4), it is possible that during the 
last part of the experiment the tumors were growing in 
the presence of low amounts of BMP7. We anticipate that 
more sustained release profiles and larger BMP7 doses 
may further prevent tumor growth. Microspheres with 
more prolonged release could be engineered from a similar 
technological platform by using polymers with longer 
degradation half-lifes such as poly(ε-caprolactone) [30].
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The tumors exposed to 0.05% BMP7 microspheres 
showed an activation of the canonical BMP signaling 
pathway. They also presented a downregulation of the 
proliferation marker PCNA and upregulation of the negative 
cell cycle regulators CDKN1A and CDKN2A, encoding the 
cell cycle inhibitory proteins p21 and p16. This would be in 
line with a previous report showing that BMP7 decreases 
proliferation of a glioma cell line through cell cycle arrest in 
the G1 phase, through the modulation of CDK2, CDKN1A 
and pRB expression [21]. We also observed a reduction in the 
expression of stem cell markers, including CD133, SOX2, 
OLIG2 and NESTIN, in agreement with other groups [6, 7]. 
Furthermore, we observed a downregulation of GFAPδ, a 
product of alternative splicing variants of GFAP-alpha, whose 
upregulation is directly related to high grade gliomas [31, 32], 
and which is also a marker of neural stem cells in human 
[33]. Contrary to previous in vitro studies [6, 7], however, 
we did not find an upregulation of the differentiation markers 
GFAPα or TUBB3 in the tumors that were exposed to 0.05% 
BMP7 microspheres. Accordingly, the BMP7-treated tumors 
were histologically indistinguishable from control tumors, 
except for their size. Given that the expression of the stem cell 
markers was reduced, it is possible that BMP7 only triggered 
an incipient differentiation state of the cells. Another plausible 
explanation is that BMP7 induced differentiation at early time 
points, while the BMP7 dose released from the microspheres 
was high, but that once the BMP7 concentration decreased 
below a certain threshold, the remaining GBM-TICs, or 
dedifferentiated cells, repopulated the tumor. This could be 
in agreement with the absence of differences in the mitotic 
and necrotic index. This lack of general cytotoxicity further 
indicates that BMP7 therapy does not affect the bulk of the 
tumor population and thus validates the selectivity of our 
strategy towards the GBM-TIC subpopulation.
MATERIALS AND METHODS
Materials
Poly(D, L-lactide-co-glycolide) 50:50 Resomer® 
RG 503 (PLGA) (MW - 35 kDa) was purchased from 
Boehringer Ingelheim (Germany). Tetronic® 1107 (T1107, 
HBL - 24 MW - 15 kDa), poly(vinyl alcohol) (PVA) (MW 
31–50 kDa) heparin sodium salt grade IA from porcine 
intestinal mucosa, soybean lecithin, and cotton seed oil 
were obtained from Sigma Aldrich (Spain). Recombinant 
human bone morphogenetic protein 7 (BMP7) (pI 8.1 
MW - 28.8 kDa), and the kit for its determination were 
purchased from PeproTech (UK) and the Abnova 
corporation (Taiwan), respectively. All other solvents and 
chemicals used were of high grade purity.
Microsphere preparation
Microspheres were prepared using a nanocomplex 
encapsulation method previously developed in our 
laboratory for the efficient entrapment of growth factors 
[11]. Two different loadings of BMP7 in the microspheres 
were tested: 0.01% and 0.05% (w/w). Microsphere 
preparation proceeded as follows: the required amount of 
BMP7 (2 μg for 0.01% loading or 10 μg for 0.05%) was 
mixed with the same amount of heparin, both dissolved 
in a total of 250 μL distilled water. The components in 
the solution were allowed to interact for 30 min at room 
temperature with mild stirring. After that time, 50 μL of a 
solution of Tetronic 1107 in water (50 mg/mL) was added 
to the mixture, letting it interact with BMP7/heparin 
complexes for other 30 min. In that way, a nanocomplex 
of BMP7/heparin/Tetronic 1107 was formed and, without 
the addition of cryoprotectants, it could be freeze-dried 
(Virtis Genesis, SP Scientific).
The freeze-drying program was the following: −30°C 
(1 h) ramped to −40°C (1 h) at 400 mTorr, freeze at −40°C 
(2 h) at 200 mTorr. Primary drying at −40°C to +20°C at 
a pressure of 20 mTorr according to the following ramp 
profile: −40°C (0 – 1080 min), −30°C (1800 min), −20°C 
(2100 min), −10°C (2220 min), 0°C (2340 min), 10°C 
(2460 min), and 20°C (2580 min). This was followed by a 
post-drying phase of 3 h at +20°C.
The resulting freeze-dried cake was resuspended 
in a solution of 20 mg of poly lactic-co-glycolic (PLGA) 
in 400 μL of acetonitrile (for a 8:1 PLGA: Tetronic 
ratio). The organic phase containing the PLGA and the 
nanocomplexes of BMP7/heparin/Tetronic 1107 was 
added dropwise to 4 mL of cottonseed oil with 0.5% (w/v) 
of soybean lecithin under magnetic stirring. To achieve 
the desired particle size the O/O emulsion droplets were 
sonicated for 20 s, prior to 10 min of gentle stirring in 
an extraction hood. Microspheres were hardened by the 
addition of 2 ml of petroleum ether and this mixture was 
stirred for 10 more minutes. Finally, microspheres were 
collected by filtration under vacuum using a nitrocellulose 
membrane (25 mm, 0.22 μm). The particles were washed 
with 5 mL of petroleum ether to avoid aggregation. The 
resulting microspheres were put in 500 μL of PVA 0.5% 
in water, freeze-dried (same procedure as above) and 
stored in a dry place under vacuum at room temperature 
until use.
Physicochemical characterization of the 
microspheres
Particle size, morphology and the structure of the 
microspheres were analyzed using Scanning Electron 
Microscopy (SEM) (EVO LS15, Zeiss Iberia, Spain). 
Samples were coated with gold-palladium under vacuum 
for proper observation. The IR spectra were made in a KBr 
disk with BRUKER IFS 66v equipment (Bruker Corp.). 
The perimeter of 150 particles were calculated using the 
Image J software, available online from the National 
Institute of Health (USA). The average particle size was 
expressed as volume mean diameter.
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In vitro release studies
Samples comprising 1 mg of microspheres loaded 
with 0.05% of BMP7 (and controls without BMP7) were 
incubated with 500 μL of PBS (pH 7.4) containing 1% 
(w/v) BSA at 37°C and under mild stirring. At several 
scheduled time points, from 24 h to 4 weeks, microspheres 
were centrifuged at 7000 g for 10 min at 4°C, and 
supernatants collected. Antigenically active BMP7, 
released from the microspheres to the supernatants, was 
quantified by ELISA according to the manufacturer’s 
instructions.
Primary cell lines and culture conditions
GBM-TIC cultures were obtained via cell 
dissociation of human GBM surgical specimens from 
patients from "Hospital 12 de Octubre" (Madrid, Spain). 
The tissues were procured after obtaining the patients´ 
written consent and with the approval of the ethics 
committee of the hospital. All procedures were performed 
according to the Spanish national law of biomedical 
investigation – Law 14/2007, of 3 July (LIB).
Fresh tissue samples were digested mechanically 
first and enzymatically thereafter, using Accumax 
(Millipore). Isolated cells were purified using a Ficoll 
gradient (GE Healthcare) and plated at a density of 
50,000 cells per milliliter in a culture medium consisting 
of Neurobasal (Invitrogen) supplemented with B27 
(1:50) (Invitrogen); GlutaMAX (1:100) (Invitrogen); 
penicillin-streptomycin (1:100, Lonza); 0.4% heparin 
(Sigma-Aldrich); and 40 ng/mL Epidermal Growth 
Factor (EGF) and 20 ng/mL of basic Fibroblast Growth 
Factor (bFGF) (Peprotech). All the primary GBM-TICs 
cultures used in this study had been proved to form tumors 
in immunodeficient mice (orthotopic and heterotopic 
transplants), which resemble the original tumors from the 
patients ([12] and Zahonero and Sanchez, manuscript in 
preparation).
Sphere formation and self-renewal assays
Sphere formation assays were carried out, plating 
2.5 cells/μL in 96-well plates (surface area, 0.3 cm2) in 
the presence or absence of BMP7 at 50 ng/mL. Results 
were analyzed after 7 days by counting the number of 
spheres (under a phase contrast microscope Zeiss Axiovert 
40 CFL) and by measuring their diameters from pictures 
of random fields captured using a ×10 objective (Image J 
software).
For the self-renewal assay, spheres from the sphere 
formation assay (that were grown in the presence or in 
the absence of BMP7) were dissociated and seeded again 
at same density (2.5 cells/μL in 96-well plates), in the 
absence of BMP7. After 7 days, the number of spheres 
was counted.
Cell growth
A fraction of the culture at any given passage point, 
consisting of 250,000 viable cells, was plated and the 
number of cells generated was quantified at the time of 
the next passage. To generate the accumulated cell growth 
curves, the ratio of cell production at each subculturing 
step was multiplied by the number of cells at the previous 
point of the curve. This procedure was repeated for each 
passage.
Quantitative real time PCR
Total RNA was extracted using a Qiagen miRNeasy 
kit. RNA samples were reverse transcribed using the 
PrimeScript® RT-PCR Kit (Takara Bio Inc., Otsu, Japan), 
and real-time qPCR was carried out using SyBR Premix 
Ex Taq 2X (Takara Bio Inc., Otsu, Japan). PCR was carried 
out using the 480 Lightcycler PCR system from Roche 
and analyzed using the 2 − DDCT method [13]. GAPDH 
served as the house-keeping gene to normalize expression 
for the genes of interest. Primer sequences for the genes 
are shown in Table 1 (Supplementary information).
Immunoblot analysis
Thirty micrograms of protein per lane were 
loaded on 12% SDS/PAGE gels and blotted onto PVDF 
membranes. Membranes were incubated with rabbit 
polyclonal anti-p-Smad1, 5, 8 (1:1000, Cell Signalling), 
rabbit polyclonal anti-Smad1, 5, 8 (1:500, Santa Cruz) 
or mouse monoclonal anti-β-actin (1:5000, Sigma) 
antibodies, followed by secondary antibodies tagged with 
HRP (1:50000; GE Healthcare), and bands were visualized 
using enhanced chemiluminescence and analyzed using 
ImageJ software. β-actin was used as a loading control.
Immunocytochemistry
Cell spheres were fixed with 4% paraformaldehide 
(PFA), washed three times with 0.1% phosphate buffer 
(PB) and incubated in 0.1% PB containing 10% fetal 
bovine serum and 0.2% Triton X-100 (blocking buffer) for 
1 h. Coverslips were incubated with rabbit polyclonal anti- 
p-Smad1, 5, 8 primary antibody overnight at 4°C. After three 
washes in 0.1% PB, immunoreactivity was detected with 
Cy3-conjugated donkey-anti-rabbit (1:1500; Jackson). Cells 
were counterstained with 4–6-diamidino-2-phenylindole 
(DAPI), washed in PB, and mounted. Immunofluorescent 
samples were analyzed and photographed in a Leica 
Spectral SP5 confocal microscope.
Mouse xenografts
Housing and animal experiments were performed 
according to European Union 86/609/EEC guidelines. 
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Protocols were also approved by the CEyBA animal care 
and use committee, from Instituto de Salud Carlos III. All 
the surgical procedures were carried out under general 
anesthesia with 8 μL/g IP anesthetic solution composed of 
10% ketamine (Imalgene) and 9.3% xylazine (Xilagesic) in 
PBS. Animals were also subcutaneously administered 4 μL/g 
of a 10% analgesic solution (Metacam) diluted in PBS. After 
the surgery, mice were woken from anesthesia with 4 μL/g of 
a 7.7% reverting solution (Antisedan) prepared in PBS.
Heterotopic xenografts were performed in athymic 
nude Foxn1nu mice (Harlan). For control groups, cells 
(1.5 × 106) were resuspended 1:1 in culture media, mixed 
with 20 mg of blank microspheres, and subsequently 
mixed with Matrigel (BD). This cell/microsphere mixture 
was injected subcutaneously into athymic nude mice. In 
the case of BMP7 treated tumors, microspheres with a 
0.01% and 0.05% (w/w) BMP7 loading were used, for a 
theoretical dose of 2 and 10 μg. The tumor volume was 
measured with a caliper when it reached a visible size until 
the animals were sacrificed.
Statistics
Data is always presented as mean ± SEM. The 
number of experiments performed in independent 
cultures/animals (n) is indicated. A 2-tailed Student’s 
t test was carried out for statistical analysis of the in vitro 
studies to compare group means. For comparisons 
between relative values, these were first normalized by 
using an arcsin transformation. *p < 0.05, **p < 0.01, 
***p < 0.001. In all analyses, the null hypothesis was 
rejected at p > 0.05.
CONCLUSIONS
In this work we have validated the therapeutic 
potential of BMP7-loaded controlled release 
microspheres as a specific treatment against GBM-TICs. 
Primary tumors treated with BMP7-loaded microspheres 
showed delayed tumor growth and lower tumor final 
volume, which could be correlated with the activation 
of the BMP canonical pathway. More importantly, these 
tumors showed a modified gene expression signature 
with loss of stem cell traits, typical of tumors with poor 
prognosis, and overexpression of cell cycle regulators. 
We propose that the combination of these GBM-TIC 
specific treatments with conventional cytoreductive 
chemo- and radiotherapies might result in improved 
survival.
Table 1: Primer sequences were designed using Primer Express 3.0 software to obtain similar 
melting temperatures (~58°C) for both oligonucleotides
Gene Forward primer Reverse primer
GAPDH 5′- GCCAAGGTCATCCATGACAACT -3′ 5′- AGGGCCATCCACAGTCTTCTG -3′
BMPR1A 5′- GAACAGGATGAAGCATTTATTCCAGT -3′ 5′- CATCTGAATCTGTTTGGCAATAGTTC -3′
BMPR1B 5′- CATGCTTTTGCGAAGTGCAG -3′ 5′- CAGGCAACCCAGAGTCATCC -3′
BMPR2 5′- GAGTGCCTTTGATGGAACATGAC -3′ 5′- ATAATCCGGGTGCTCCTTCA -3′
BMP7 5′- CACAACCTGGGCTTACAGCTCT -3′ 5′- CTTGAAGAAGGCCACCATGAAG -3′
SOX2 5′- ACACCAATCCCATCCACACT -3′ 5′- GCAAACTTCCTGCAAAGCTC -3′
CD133 5′- TGGATGCAGAACTTGACAACGT -3′ 5′- ATACCTGCTACGACAGTCGGTGG -3′
NESTIN 5′- CCTCCTGGAGGCTGAGAACTC -3′ 5′- AAGGCTGGCACAGGTGTCTC -3′
OLIG2 5′-CAGAAGCGCTGATGGTCATA -3′ 5′- TCGGCAGTTTTGGGTTATTC -3′
TUBB3 5′- TAGTGGAGAACACAGACGAGA -3′ 5′- CTGCTGTTCTTACTCTGGATG -3′
GFAPα 5′-ACATCGAGATCGCCACCTAC -3′ 5′- ATCTCCACGGTCTTCACCAC -3′
GFAPδ 5′-ACATCGAGATCGCCACCTAC -3′ 5′- CGGCGTTCCATTTACAATCT -3′
PCNA 5′-GGAGGCTCTAGCCTGACAAA -3′ 5′- CTGAGACTTGCGTAAGGGAA -3′
CDKN1A 5′- GTGGCCTTGTCGCTGTCTTG -3′ 5′- TCGGCGCTTGGAGTGATAGAA -3′
CDKN2A 5′- ACCGGAGGAAGAAAGAGGAG -3′ 5′- GCGCTACCTGATTCCAATTC -3′
All quantitative PCR primers were designed between exons with a resultant amplicon of less than 150 bp in length. Primers 
contained 60% to 80% G/C and were no longer than 26 bp. Lyophilized primers (Sigma-Aldrich) were resuspended in 
ddH2O to a stock solution of 100 mmol/L. The thermal cycler conditions were as follows: 95°C for 10 minutes, followed by 
45 cycles of 95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 10 seconds
Oncotarget10962www.impactjournals.com/oncotarget
ACkNOwLEDGMENTS
This study was supported by grants from: Ministerio 
de Economía y Competitividad, Fondo de Investigación 
Sanitaria (PI12/101 to HM; PI12/00775 to PSG; 
PS09/1786 to MGF and PI13/01258 to AHL), Comunidad 
de Madrid (S2010/BMD-2336 to HM), Xunta de Galicia 
(EM2013/042 to MGF), Fundación BBVA (2014-PO010 
to MGF) and Ministerio de Economía y Competitividad, 
Red Temática de Investigación Cooperativa en Cáncer 
(RD12/0036/0027 to PSG and AHL).
PGG was recipient of a “Sara Borell” postdoctoral 
fellowship, and MdF of a “Miguel Servet” contract from 
Ministerio de Economía y Competitividad. We are grateful 
to María Díaz, Rafael Hortigüela, Raquel Pérez y Daniel 
Baztán for helping with confocal microscopy, primer 
design, mouse histology and animal care, respectively.
CONFLICTS OF INTEREST
MGF is a designated co-inventor of the patent PCT/
ES2013/070655: WO2014044894 (A1), which covers the 
drug delivery technology described in this publication. As 
co-inventor he might be subject to potential economical 
compensation in case of patent licensing.
Editorial note
This paper has been accepted based in part on peer-
review conducted by another journal and the authors’ 
response and revisions as well as expedited peer-review 
in Oncotarget
REFERENCES
1. Das S, Srikanth M, Kessler JA. Cancer stem cells and gli-
oma. Nat Clin Pract Neurol. 2008; 4:427–435.
2. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells 
in nervous system tumors. Oncogene. 2004; 23:7267–7273.
3. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, 
Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, 
Fine HA. Tumor stem cells derived from glioblastomas cul-
tured in bFGF and EGF more closely mirror the phenotype 
and genotype of primary tumors than do serum-cultured cell 
lines. Cancer Cell. 2006; 9:391–403.
4. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda 
E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL. 
Bone morphogenetic proteins inhibit the tumorigenic poten-
tial of human brain tumour-initiating cells. Nature. 2006; 
444:761–765.
5. Singh A, Morris RJ. The Yin and Yang of bone morpho-
genetic proteins in cancer. Cytokine Growth Factor Rev. 
2010; 21:299–313.
6. Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, 
Herrmann IM, Graf D, Mitsiadis T, Herold-Mende C, 
Besser D, Synowitz M, Kettenmann H, Glass R. Bone 
morphogenetic protein-7 release from endogenous neural 
precursor cells suppresses the tumourigenicity of stem-like 
glioblastoma cells. Brain. 2010; 133:1961–1972.
7. Tate CM, Pallini R, Ricci-Vitiani L, Dowless M, 
Shiyanova T, D’Alessandris GQ, Morgante L, Giannetti S, 
Larocca LM, di MS, Rowlinson SW, De MR, Stancato L. 
A BMP7 variant inhibits the tumorigenic potential of 
glioblastoma stem-like cells. Cell Death Differ. 2012; 
19:1644–1654.
8. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, 
Kotliarova S, Kotliarov Y, Walling J, Ahn S, Kim M, 
Totonchy M, Cusack T, et al. Epigenetic-mediated dysfunc-
tion of the bone morphogenetic protein pathway inhibits 
differentiation of glioblastoma-initiating cells. Cancer Cell. 
2008; 13:69–80.
9. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based 
tissue engineering: general approaches and a review of 
recent developments. J R Soc Interface. 2011; 8:153–170.
10. Zhou J, Atsina KB, Himes BT, Strohbehn GW, Saltzman 
WM. Novel delivery strategies for glioblastoma. Cancer J. 
2012; 18:89–99.
11. Reguera-Nunez E, Roca C, Hardy E, de la Fuente M, 
Csaba N, Garcia-Fuentes M. Implantable controlled release 
devices for BMP-7 delivery and suppression of glioblas-
toma initiating cells. Biomaterials. 2014; 35:2859–2867.
12. Pozo N, Zahonero C, Fernandez P, Linares JM, Ayuso A, 
Hagiwara M, Perez A, Ricoy JR, Hernandez-Lain A, 
Sepulveda JM, Sanchez-Gomez P. Inhibition of DYRK1A 
destabilizes EGFR and reduces EGFR-dependent glioblas-
toma growth. J Clin Invest. 2013; 123:2475–2487.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expres-
sion data using real-time quantitative PCR and the 2(-Delta 
Delta C(T)) Method. Methods. 2001; 25:402–408.
14. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, 
Kaplan RS, Linet MS. Cancer surveillance series 
[ corrected]: brain and other central nervous system cancers: 
recent trends in incidence and mortality. J Natl Cancer Inst. 
1999; 91:1382–1390.
15. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS 
statistical report: primary brain and central nervous system 
tumors diagnosed in the United States in 2005–2009. Neuro 
Oncol. 2012; 14:v1–49.
16. Meacham CE, Morrison SJ. Tumour heterogeneity and 
 cancer cell plasticity. Nature. 2013; 501:328–337.
17. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, 
Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 
Glioma stem cells promote radioresistance by preferential 
activation of the DNA damage response. Nature. 2006; 
444:756–760.
18. Liu C, Tian G, Tu Y, Fu J, Lan C, Wu N. Expression  pattern 
and clinical prognostic relevance of bone morphogenetic 
protein-2 in human gliomas. Jpn J Clin Oncol. 2009; 
39:625–631.
Oncotarget10963www.impactjournals.com/oncotarget
19. Wu Q, Yao J. BMP4, a new prognostic factor for glioma. 
World J Surg Oncol. 2013; 11:264.
20. Duggal R, Geissinger U, Zhang Q, Aguilar J, Chen NG, 
Binda E, Vescovi AL, Szalay AA. Vaccinia virus express-
ing bone morphogenetic protein-4 in novel glioblastoma 
orthotopic models facilitates enhanced tumor regression and 
long-term survival. J Transl Med. 2013; 11:155.
21. Klose A, Waerzeggers Y, Monfared P, Vukicevic S, 
Kaijzel EL, Winkeler A, Wickenhauser C, Lowik CW, 
Jacobs AH. Imaging bone morphogenetic protein 7 induced 
cell cycle arrest in experimental gliomas. Neoplasia. 2011; 
13:276–285.
22. Zhou Z, Sun L, Wang Y, Wu Z, Geng J, Miu W, Pu Y, 
You Y, Yang Z, Liu N. Bone morphogenetic protein 4 
inhibits cell proliferation and induces apoptosis in glioma 
stem cells. Cancer Biother Radiopharm. 2011; 26:77–83.
23. Liu B, Chen Q, Tian D, Wu L, Dong H, Wang J, Ji B, 
Zhu X, Cai Q, Wang L, Zhang S. BMP4 reverses multi-
drug resistance through modulation of BCL-2 and GDNF 
in  glioblastoma. Brain Res. 2013; 1507:115–124.
24. Persano L, Pistollato F, Rampazzo E, Della PA, 
Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R, 
Basso G. BMP2 sensitizes glioblastoma stem-like cells 
to Temozolomide by affecting HIF-1alpha stability and 
MGMT expression. Cell Death Dis. 2012; 3:e412.
25. Gonzalez-Gomez P, Anselmo NP, Mira H. BMPs as thera-
peutic targets and biomarkers in astrocytic glioma. Biomed 
Res Int. 2014; 2014:549742.
26. d’Angelo I, Oliviero O, Ungaro F, Quaglia F, Netti PA. 
Engineering strategies to control vascular endothelial 
growth factor stability and levels in a collagen matrix 
for angiogenesis: the role of heparin sodium salt and the 
PLGA-based microsphere approach. Acta Biomater. 2013; 
9:7389–7398.
27. Csaba N, Caamano P, Sanchez A, Dominguez F, 
Alonso MJ. PLGA:poloxamer and PLGA:poloxamine 
blend nanoparticles: new carriers for gene delivery. 
Biomacromolecules. 2005; 6:271–278.
28. Freitas S, Merkle HP, Gander B. Microencapsulation by 
solvent extraction/evaporation: reviewing the state of the art 
of microsphere preparation process technology. J Control 
Release. 2005; 102:313–332.
29. Jensen JB, Parmar M. Strengths and limitations of the neu-
rosphere culture system. Mol Neurobiol. 2006; 34:153–161.
30. Nair LS, Laurencin CT. Biodegradable polymers as 
 biomaterials. Prog Polym Sci. 2007; 32:762–798.
31. Choi KC, Kwak SE, Kim JE, Sheen SH, Kang TC. 
Enhanced glial fibrillary acidic protein-delta expression in 
human astrocytic tumor. Neurosci Lett. 2009; 463:182–187.
32. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, 
Russell R, Bayani J, Head R, Lee M, Bernstein M, 
Squire JA, Smith A, Dirks P. Glioma stem cell lines 
expanded in adherent culture have tumor-specific pheno-
types and are suitable for chemical and genetic screens. Cell 
Stem Cell. 2009; 4:568–580.
33. Roelofs RF, Fischer DF, Houtman SH, Sluijs JA, Van HW, 
Van Leeuwen FW, Hol EM. Adult human subventricular, 
subgranular, and subpial zones contain astrocytes with a 
specialized intermediate filament cytoskeleton. Glia. 2005; 
52:289–300.
